ECDC Warns 12 European Countries Face Domestic Spread of Ceftriaxone-Resistant Gonorrhea
Updated
Updated · studyfinds.com · Jul 17
ECDC Warns 12 European Countries Face Domestic Spread of Ceftriaxone-Resistant Gonorrhea
3 articles · Updated · studyfinds.com · Jul 17
Summary
Cases in 12 European countries show ceftriaxone-resistant gonorrhea is now spreading person to person inside Europe, including among patients with no travel history, according to a new ECDC risk assessment.
Britain, Sweden, France and Germany drove the upturn: Britain logged 29 cases in 2025 and 17 more by June 2026, while France identified at least 17 multidrug- or extensively drug-resistant infections since January 2025.
Six treatment failures—all in Britain and all throat or rectal infections—show the pressure on first-line therapy; four cleared after repeat ceftriaxone plus azithromycin, while two needed intravenous ertapenem.
ECDC still rates overall risk to the general sexually active population as low, but says narrowing treatment options and under-detection could let clusters grow, especially because many diagnoses are never cultured for resistance testing.
With Europe’s last-line gonorrhea drug failing, why are new FDA-approved treatments not yet available to stop the domestic spread?
After a major vaccine trial failed, can AI-discovered antibiotics become the last hope against Europe's untreatable gonorrhea superbug?
The Rapid Spread of Drug-Resistant Gonorrhea in Europe: Latest Data, Treatment Challenges, and Public Health Responses (2024-2026)
Overview
This report highlights the growing threat of drug-resistant gonorrhea in Europe, based on extensive surveillance by Euro-GASP, which collected thousands of gonococcal samples across 24 countries in 2023. Researchers tested these samples for resistance to key antibiotics, including ceftriaxone, and tracked tetracycline resistance to inform new prevention strategies. Despite these efforts, challenges remain due to incomplete data and a focus on urogenital samples, which may miss hidden infections. The findings underscore the urgent need for better surveillance, new treatments, and stronger public health measures to control the spread of resistant gonorrhea.